Cleo Diagnostics files patents for ovarian cancer test

Cleo Diagnostics has filed two provisional patents for its ovarian cancer screening test, covering biomarker combinations for early detection.

The filings cover the application of these biomarker combinations in the early detection of ovarian cancer.

They follow the company’s recent start of its screening development programme and are intended to establish an initial intellectual property priority position around the technologies being developed.

Cleo Diagnostics said it plans to file an international application under the Patent Cooperation Treaty within the 12-month priority period, with the aim of seeking protection across selected commercial markets as development work continues.

The patent applications were submitted ahead of the release of the company’s initial proof-of-concept screening data, which is expected in the fourth quarter of calendar year 2026.

The screening test programme builds on Cleo Diagnostics’ existing biomarker platform and clinical expertise, developed through its Pre-Surgical Ovarian Cancer Test programme.

The company is progressing multiple applications of its biomarker technology across different stages of ovarian cancer detection, including pre-surgical assessment, recurrence monitoring and potential future screening applications.

The company’s technology platform is based on the biomarker CXCL10, a protein the company says has been the subject of more than 15 years of scientific research and development.

Cleo Diagnostics states that CXCL10 is produced early in ovarian cancer and may help distinguish malignant from benign conditions.

Cleo Diagnostics is also continuing to advance its Pre-Surgical Ovarian Cancer Test programme, which the company said is progressing towards planned regulatory activities.

The company said medical technology development carries risks related to clinical validation, regulatory approvals, intellectual property protection, funding requirements and commercial adoption.

Patent filings provide intellectual property protection but do not confirm successful product development, regulatory approval or commercialisation. Diagnostic technologies require further clinical evaluation and validation before they can be adopted for wider healthcare use.

Cleo Diagnostics’ shares were trading at AUD 0.30, up nearly 6 per cent, on 30 September 2026 at 1:16pm.